Citations

Clear

9383 citation(s) found for "Thomas, PS".

Abstract 1853: Monoclonal B-cell Lymphocytosis (MBL) has increased incidence in non-Hodgkin lymphoma (NHL) Families
Achenbach, Sara J., Call, Timothy G. , Vachon, Celine M. , Ansell, Stephen M. , Hanson, Curtis A. , Slager, Susan L. , Rabe, Kari G. , Vachon, Celine M. , Habermann, Thomas M. , Kay, Neil E. , Shanafelt, Tait D. , Cerhan, James R.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 1853-1853

10.1158/1538-7445.am10-1853 Get It

Abstract Background. MBL is defined as a monoclonal expansion of B lymphocytes (< 5 × 109/L) in the blood without associated lymphadenopathy or organomegaly; MBLs with a chronic lymphocytic leukemia (CLL) immunophenotype have been termed as CLL-like MBL. The prevalence of CLL-like MBL in the general population is 3.5-12% but increases with age; however, the frequency is even higher (∼13-18%) among unaffected relatives from CLL families (i.e., families with two or more CLL members). We and others have found that a small proportion of individuals with CLL-like MBL individuals and lymphocytosis will progress to CLL requiring treatment (∼1.1% per year). Because CLL and NHL have been shown to aggregate together within families, suggesting a shared pathogenesis, we evaluated the frequency of MBL in NHL families. Methods. Individuals were obtained from an ongoing study of NHL families (i.e., families with 2 or more NHL members). However, we limited to NHL families with at most 1 individual with CLL due to the known increased frequency of MBL in CLL families. Multi-color flow cytometry was performed on fresh peripheral blood samples. A CBC and differential count was simultaneously obtained using an automated blood cell counter. Five possible flow diagnoses were defined as: CLL-like MBL (CD5+CD20dim), atypical MBL (CD5+CD20bright), non-CLL like MBL (CD5−), and normal immunophenotype (NIPT). Medical records of NHL cases were reviewed to confirm disease. Results. A total of 30 individuals from 16 NHL families had available flow cytometry results. The mean age at flow analysis was 56 years (range 37− 83 years). We identified 5 individuals with MBL from 4 families: 3 of the 6 had CLL-like MBL, 1 had atypical MBL, and 1 had non-CLL like MBL. The remaining 25 individuals had a NIPT. Thus, the MBL rate in NHL families is 17% (5/30). Among the CD5+ MBL (both CLL-like and atypical MBL) individuals, all were female and the mean absolute lymphocyte count was 1.4 × 109/L. Of interest, 1 of the CLL-like MBL individuals is from a family where two members had monoclonal gammopathy of uncertain significance (MGUS). Conclusion: Our data show that MBLs of various phenotypes can be found at a higher prevalence in NHL families than that of the general population. Further, the frequency of MBL in NHL families is comparable to that of CLL families. Although more work is needed, our results suggest that MBL may be clustering within NHL families, and thus support a possible common inherited predisposition of NHL and CLL, with MBL signifying a shared early pathogenetic step. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1853.
Abstract 1833: Body mass index and physical activity in relation to risk of non-Hodgkin lymphoma (NHL)
Kelly, Jennifer L., Fredericksen, Zachary S., Wang, Alice H., Liebow, Mark , Macon, William R. , Thompson, Carrie A. , Shanafelt, Tait D. , Habermann, Thomas M. , Kay, Neil E. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 1833-1833

10.1158/1538-7445.am10-1833 Get It

Abstract Background: Obesity has been linked to NHL risk in some studies, and may be stronger for obesity in early adulthood (ages 18-20). There has only been limited evaluation of physical activity and risk of NHL, particularly physical activity earlier in life. The purpose of this study was to evaluate the association of body mass index (BMI), physical activity (PA), and NHL risk during adulthood and at age 18. Methods: Self-reported anthropometrics and PA were collected in a clinic-based study of 954 newly diagnosed NHL cases and 1146 controls enrolled at the Mayo Clinic from 2002-2008. PA variables included duration and frequency of mild, moderate, and strenuous PA two years prior to case diagnosis or control selection, strenuous activity at age 18 (any vs. none), and height and weight at both time periods. An overall PA index was estimated by weighting the reported duration and frequency of each PA intensity by the average energy requirement (defined in METs) to obtain an average MET-minutes/week for each participant. BMI was calculated as weight (kg) divided by height (m) squared. Odds Ratios (OR), 95% confidence intervals (CI), and test for trend were estimated using unconditional logistic regression adjusted for the age, gender, and residence. Continuous variables were divided into quartiles according to the distribution among the controls; results are reported for the highest vs. lowest category or quartile unless otherwise specified. Results: The mean age at diagnosis/enrollment was 61 for both cases and controls; 47% and 43% of the cases and controls, respectively, were female. The most common NHL subtypes were CLL/SLL (32%), follicular lymphoma (FL; 26%), and diffuse large B-cell lymphoma (DLBCL; 21%). BMI 2 years prior to diagnosis was not associated with NHL risk (OR=1.21, p-trend=0.13), while there was a positive association with BMI at age 18 (OR=1.40, p-trend=0.001). There was no association of the PA index with risk (OR=0.91, p-trend=0.29). Furthermore, frequency of walking (OR=0.71, p-trend 0.43), mild (OR=1.30, p-trend=0.64), moderate (OR=0.99, p-trend=0.75), and strenuous (OR=0.77, p-trend=0.20) PA were not associated with NHL risk when evaluated individually. However, there was a suggestive weak inverse association between strenuous activity at age 18 and NHL risk (OR=0.85, 95% CI 0.71-1.05). On exploratory analysis, the association of BMI at age 18 with NHL risk was specific to DLBCL (OR=1.84, p-trend=0.002) and CLL/SLL (OR=1.25, p-trend=0.044) but not FL; all other results were similar across these subtypes. Conclusions: We did not observe an association between adult BMI and NHL risk; however a higher BMI in early adulthood was associated with NHL risk, consistent with limited prior reports. We found little evidence to support an association between PA in either early adulthood or later in life and NHL risk. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1833.
Abstract 914: Xenobiotic metabolizing SNPs and ovarian cancer risk
White, Kristin L., Sellers, Thomas A. , Phelan, Catherine, Cunningham, Julie M. , Schildkraut, Joellen M. , Berchuck, Andy, Goode, Ellen L. , Vierkant, Robert A. , Fridley, Brooke L. , Olson, Janet E. , Beesley, Jonathan , Chenevix‐Trench, Georgia

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 914-914

10.1158/1538-7445.am10-914 Get It

Abstract As the leading cause of mortality among gynecologic cancers, it is critical to increase understanding of ovarian cancer pathogenesis, which remains largely unknown. Several xenobiotic metabolizing enzymes are responsible for processing and inactivating carcinogens that could initiate ovarian carcinogenesis. Here, we hypothesize that single-nucleotide polymorphisms (SNPs) in genes encoding xenobiotic metabolizing enzymes may be associated with differential risk of ovarian cancer. Cases with epithelial ovarian cancer (N=930) and controls (N=1,037), frequency-matched on age and geographic residence, were enrolled at Mayo Clinic and Duke University, and genotyped at 163 tagSNPs in EPHX1, SULT1E1, ADH5, ADH4, ADH6, ADH1A, ADH1B, ADH1C, NQO2, NAT1, NAT2, GSTP1, CYP19A1, CYP1A1, CYP1A2, and NQO1 using an Illumina GoldenGate™ BeadArray array. Logistic regression was used to estimate odds ratios (ORs) and adjust for population structure and other potential confounders, including oral contraceptive use, parity, and family history. SNP-specific statistical analyses identified several noteworthy results including an association with increased risk of ovarian cancer with a SNP (rs2917666) in NAD(P)H dehydrogenase, quinone 1 (NQO1) (per-allele OR 1.16, 95% confidence interval (CI) 1.01-1.33, p=0.04). The SNP rs1051740 in epoxide hydrolase 1, microsomal (xenobiotic) (EPHX1) was suggestive of increased risk of invasive serous disease (TT v CT OR 0.85, 95% CI 0.66-1.09, TT v CC 1.29, 95% CI 0.89-1.88, p=0.09). In an effort to replicate these observations, a subset of 11 SNPs with a p-value < 0.10 were then genotyped in 727 invasive cancer cases and 1,065 controls from an Australian ovarian cancer study using a Sequenom iPlex assay. Results of combined analyses confirmed an association between EPHX1 rs1051740 and increased invasive serous ovarian cancer risk (TT v CT OR 0.99, 95% CI 0.77-1.29, TT v CC OR 1.61, 95% CI 1.23-2.11, p=0.001; recessive OR 1.61, 95% CI 1.25-2.09, p=0.001). This gene is involved in the activation and detoxification of tobacco-derived carcinogens, and smoking has been associated with the mucinous histologic subtype of ovarian cancer. Analyses by histological subtype and gene-environment interaction analyses considering genotype in conjunction with tobacco use and alcohol intake are underway. Due to the important role of EPHX1 in metabolizing pro-carcinogens and the observed association between rs1051740 and risk of invasive serous disease, an examination of this SNP in a larger ovarian cancer consortium is warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 914.
Abstract 897: Association of inherited variants in HGF and ovarian cancer survival time
Cunningham, Julie M. , Hartmann, Lynn C. , Armasu, Sebatian M., Sicotte, Hugues , Phelan, Catherine M., White, Kristin L., Sutphen, Rebecca , Kellemen, Linda E., Kalli, Kimberly R., Keeney, Gary L., Schildtkraut, Joellen M., Sellers, Thomas A. , Goode, Ellen L. , Fridley, Brooke L. , Vierkant, Robert A. , Tsai, Ya-Yu , Couch, Fergus J.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 897-897

10.1158/1538-7445.am10-897 Get It

Abstract Using data from patients with invasive epithelial ovarian cancer, we sought to examine whether overall survival was associated with common inherited variation in candidate genes and genomic regions including those involved in angiogenesis, mitosis, and regions of interest from genome-wide association and expression studies. We conducted a two-stage analysis based on Mayo Clinic patients with replication of peak results in the Cancer Genome Atlas (TCGA). Ovarian cancer patients (N=312) seen at the Mayo Clinic diagnosed from 1999 to 2006 with median follow-up of 3.7 years (range, 0.1 − 9.5 years) and 172 observed deaths were analyzed at 993 single nucleotide polymorphisms (SNPs) in 179 genes. For all patients and for serous patients only (N=192 with 129 observed deaths), Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for each SNP, adjusted for other prognostic factors. Twenty-nine SNPs in ten genes revealed p < 0.01 among all cases or among serous cases only, including 21 independent SNP at r2=0.9; analyses within four genes (HGF, PLG, PRKACB, and DCTN5) yielded p < 0.001. The strongest result was in HGF at rs1800793 (all cases: HR 1.7, 95% CI 1.3 − 2.2, p-trend 1.9 E-5; serous cases: HR 1.6, 95% CI 1.2 − 2.2, p-trend 1.8 E-3). A correlated SNP rs2214825 also showed association (r2=0.76; all cases: HR 1.4, 95% CI 1.1 − 1.8, p-trend 3.3 E-3; serous cases: HR 1.4, 95% CI 1.0 − 1.9, p-trend 0.03), and PCA gene-level tests of the HGF locus were also significantly associated with survival (all cases, p=3.7 E-4; serous cases, p=0.01). Among all cases, differential survival was also associated with DCTN5 rs12447304 (HR 1.8, 95% CI 1.3-2.6; p=7.1 E-4), and among serous cases, with PLG rs783173 (HR 1.6, 95% CI 1.2 − 2.0, p = 8.1 E-4) and PRKACB rs1402694 (HR 1.7, 95% CI 1.3 − 2.2, p=3.2 E-4). We then examined SNPs in the most suggestive gene, HGF, using data from TCGA which had genotyped four overlapping HGF SNPs in 350 invasive cases (188 deaths). Covariate-adjusted TCGA analysis at rs2214825 revealed consistent results (HR 1.7, 95% CI 1.3-2.2, p=1.4 E-4) as did analyses of three other HGF SNPs (HR range 1.3 to 1.5, p range 3.4 E-3 to 0.049); correlation between SNP genotypes and HGF expression was also observed (p=1.4 E-3, rs2214825, probe 210997_at). While this is the first report of SNPs in HGF, it has long been known that the HGF signaling pathway, activated by HGF ligation of c-MET, plays a key role ovarian cancer cell growth, migration, and invasion. c-MET is overexpressed in 40%-60% of ovarian tumors, and high overexpression is associated with lower overall survival. In addition, HGF has been shown to enhance the response of ovarian cancer cells to low doses of paclitaxel and cisplatin by activating the intrinsic apoptotic pathway, leading to cancer cell death. These results now suggest that inherited differences in HGF among women with invasive disease may play a role in survival, holding potential clues for tailored avenues of treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 897.
Abstract 4828: Longitudinal breast density and risk of breast cancer
Vachon, Celine M. , Sellers, Thomas A. , Ghosh, Karthik, Brandt, Kathleen R. , Olson, Janet E., Jensen, Matthew R. , Pruthi, Sandhya , Morton, Marilyn J., Serie, Daniel, Vachon, Celine M. , Scott, Christopher G. , Olson, Janet E. , Pankratz, V. Shane

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4828-4828

10.1158/1538-7445.am10-4828 Get It

Abstract Introduction: Mammographic breast density is one of the strongest risk factors for breast cancer and appears to be modifiable. However, whether longitudinal changes in density are associated with breast cancer risk is unknown. We hypothesize that decreases in breast density are associated with reduced breast cancer risk. Methods: The Mayo Mammography Health Study cohort enrolled 19,924 women having a screening mammogram (mgm) at the Mayo Clinic, Rochester, between 2003 and 2006. Participants were 35 years and older, had no prior breast cancer and lived in the tri-state area (MN, IA and WI). Risk factor data were collected through self-administered questionnaire and clinic databases. Incident breast cancers were identified through tumor registries (Mayo Clinic, MN, IA, WI). The BI-RADS, 4-category clinical density measure (fatty, scattered density, heterogeneous density and extreme density) was available on all mgms performed after 1996. A case-cohort design consisting of incident cases (n=241) and a random selection of the cohort (n=2300, 28 developed cancer) was used to examine the association between change in BI-RADS density and breast cancer. BI-RADS densities measured from the earliest available, and enrollment mgms (average 6 years apart) were used to assess density change. Proportional hazards regression was performed to estimate the hazard ratio (HR) associated with a change in one or more BI-RADS density categories over time, relative to staying within the same category. Age was used as the time scale, and the subcohort was weighted by the inverse of the sampling proportion. Analyses were adjusted for age, years between mgms, BI-RADS density at earliest mgm, and changes in BMI, postmenopausal hormone use, and menopausal status. Results: Longitudinal analyses were conducted on the 219 cases and 1900 non-cases in the subcohort with at least one mgm available prior to enrollment mgm. Compared to the subcohort, cases were older (56.8 vs. 52.9 years), more likely postmenopausal (73.4% vs. 61.6%), had higher BMI (29.0 vs 28.1) and were more frequently screened (8.0 vs. 6.9 pre-enrollment mgms). As expected, cases were more likely to have extreme density (BI-RADS=4) at earliest mgm than non-cases (16.2% vs 14.3%). Cases were less likely than non-cases to experience a reduction of one density category or more (37.0% vs 38.6%) following earliest mgm. Adjusting for potential confounders, women who decreased one BI-RADS category or more over an average 6 years were at reduced risk of breast cancer (HR=0.72, 95%CI: 0.50-0.99) compared to those whose density was unchanged. However, women who increased one or more BI-RADS categories had suggestion of increased risk (HR=1.52, 95%CI: 0.97-2.4). Conclusion: Women with a decrease in BI-RADS density category over 6 years may have decreased breast cancer risk relative to women whose breast density category remains stable. Two measures of breast density may inform women's risk beyond a measure at one point in time. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4828.
Abstract 4724: A novel region on 8q24.21 is associated with ovarian cancer susceptibility
Chen, Zhihua , Permuth‐Wey, Jenny, Iversen, Edwin S. , Cunningham, Julie M. , Fenstermacher, David, Sutphen, Rebecca , Phelan, Catherine M., Narod, S A, Schildkraut, Joellen M. , Goode, Ellen L. , Sellers, Thomas A. , Tsai, Ya-Yu , Chen, Y. Ann , Risch, Harvey A. , Barnholtz‐Sloan, Jill S. , Vierkant, Robert A. , Fridley, Brooke L.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4724-4724

10.1158/1538-7445.am10-4724 Get It

Abstract Recent GWAS have identified and confirmed associations between several SNPs in the gene desert located on chromosome 8q24 with risk of cancers of the breast, prostate, glioma, bladder and colorectum. Evidence supporting an association with ovarian cancer is limited and inconsistent. Here we evaluate preliminary results in the 8q24 region from stage I of an ongoing invasive epithelial ovarian cancer GWAS among 1864 cases (1096 serous cases) and 1912 controls. All subjects were self-reported non-Hispanic non-Jewish Caucasian, and were genotyped with the Illumina 610quad Chip. Samples and SNPs with call rates less than 95% were excluded (9.6% and 9.9%, respectively) as well as 128 subjects with ambiguous gender, unresolved identical genotypes and less than 80% European ancestry were also excluded. Our most significant hit in the region was rs6651252 located at 8q24.21 with p = 0.000125 for all ovarian cancer, and 1.02*10−5 for serous cases only. This region is located approximately 849 kb downstream of the previous 8q24.21 findings on other cancers, and was not in linkage disequilibrium with any of the haplotype blocks reported previously. We further examined the block structure of this region with eight genotyped SNPs located within 129.61 to 129.64 MB (rs10088218, rs1516973, rs1516975, rs16903097, rs10098821, rs6651252, rs1561928, and rs1561927) and performed haplotype analysis to evaluate the association with ovarian cancer risk. One haplotype (AAGCAGGG, estimated frequency=0.11) was significantly associated with decreased ovarian cancer risk with an odds ratio of 0.67 (all cases, 95% CI: 0.78-0.91, p=0.0026, empirical p= 0.0020). This region contains no known genes, but it is located upstream and overlaps with a known copy number variation (CNV) reported by Redon et al. (2006). Previous published literature on array CGH and CNV results from TCGA (The Cancer Genome Atlas) also indicate that the 8q24.21 region is associated with frequent gains/amplification in ovarian tumors. Combined analysis of SNPs and CNV identified in this region is underway to elucidate the joint effect of these two types of genetic variation on ovarian cancer risk. Our result indicates a novel locus on 8q24.21 is associated with epithelial ovarian cancer susceptibility. Haplotype analysis reveals one specific haplotype that is associated with decreased ovarian cancer risk compared to the most common haplotype. Given previous 8q24 findings from other cancers and evidence from publicly available resources, fine-mapping and resequencing of this region is warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4724.
Abstract 4718: Inherited variants in relapse-associated genes and risk of ovarian cancer
Hartmann, Lynn C. , Fredericksen, Zachary S., White, Kristin L., Elliott, Elaine A., Phelan, Catherine M., Iversen, Edwin S. , Peethambaram, Prema P. , Kalli, Kimberly R., Kosel, Matthew , Shridhar, Vijayalakshmi, Rider, David N., Liebow, Mark , Cunningham, Julie M. , Schildkraut, Joellen M. , Sellers, Thomas A. , Goode, Ellen L. , Peedicayil, Abraham , Vierkant, Robert A. , Fridley, Brooke L. , Tsai, Ya-Yu , Berchuck, Andrew , Couch, Fergus J. , Larson, Melissa C.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4718-4718

10.1158/1538-7445.am10-4718 Get It

Abstract Background: We previously identified a panel of genes associated with outcome of ovarian cancer. The purpose of the current study was to assess whether variants in these genes correlated with ovarian cancer risk. Methods and Findings: Women with and without invasive ovarian cancer (749 cases, 1,041 controls) were genotyped at 136 single nucleotide polymorphisms (SNPs) within 13 candidate genes. Risk was estimated for each SNP and for overall variation within each gene. At the gene-level, variation within MSL1 (male-specific lethal-1 homolog) was associated with risk of serous cancer (p=0.03); haplotypes within PRPF31 (PRP31 pre-mRNA processing factor 31 homolog) were associated with risk of invasive disease (p=0.03). MSL1 rs7211770 was associated with decreased risk of serous disease (OR 0.81, 95% CI 0.66-0.98; p=0.03). SNPs in MFSD7, BTN3A3, ZNF200, PTPRS, and CCND1A were inversely associated with risk (p<0.05), and there was increased risk at HEXIM1 rs1053578 (p=0.04, OR 1.40, 95% CI 1.02-1.91). Conclusions: Tumor studies can reveal novel genes worthy of follow-up for cancer susceptibility. Here, we found that inherited markers in the gene encoding MSL1, part of a complex that modifies the histone H4, may decrease risk of invasive serous ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4718.
Abstract 4603: Role of endoxifen as an antiestrogen: Effects on oncogene expression and polyamine pathway
Thomas, TJ, John, Shali, Hsu, Hui‐Chen , Yang, PingAr, Hyvönen, Mervi T. , Alhonen, Leena, Keinänen, Tuomo A. , Maharvi, Ghulam M., Fauq, Abdul H. , Patel, Sonam

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 4603-4603

10.1158/1538-7445.am10-4603 Get It

Abstract The nonsteroid antiestrogen tamoxifen [trans-1-(4-b-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene] is the most commonly used endocrine treatment for estrogen receptor α (ERα)-positive breast cancer in pre- and post-menopausal women, and it has helped to reduce breast cancer death rate by one third. Tamoxifen is extensively metabolized, and several metabolites have been detected in human serum. It is metabolized to 4-hydroxytamoxifen and N-desmethyltamoxifen by the action of CYP2D6 and CYP3A4/5 enzymes, respectively. N-desmethyltamoxifen and 4-hydroxy-tamoxifen are further converted to endoxifen by the action of these enzymes. Steady state levels of serum tamoxifen/metabolite are achieved within 4 weeks of continuous administration of the drug. The therapeutic efficacy of tamoxifen is determined by the distribution of the drug into tissues and the availability of the parent drug and its active metabolites in target tissues. Recent reports indicate that endoxifen might act as an antiestrogen. In order to examine the mechanism of action of endoxifen on an ERα-positive breast cancer cell line, MCF-7, we determined the effects of 100, 250, 500 and 1000 nM concentrations of this agent on cell growth, c-myc oncogene expression and activity of the polyamine biosynthetic enzymes. MCF-7 breast cancer cells were treated for 1, 3 or 5 days with endoxifen. Endoxifen had a growth inhibitory effect on MCF-7 cells by day 3 and 5 of treatment, as measured by cell number. Estradiol increased cell number by >2-fold compared to untreated control by day 5 of treatment, whereas endoxifen inhibited the estrogenic effect. c-myc gene expression was increased by a significant 2- to 3-fold by 4 nM estradiol in 2 and 4 hours of treatment, while 250 and 500 nM endoxifen suppressed the increase in c-myc gene expression, as measured by real-time qPCR experiment. In the absence of estradiol, endoxifen slightly (1.5 fold) increased c-myc gene expression. Endoxifen decreased ornithine decarboxylase (ODC) and S-adenosine methyl decarboxylase (AdoMetDC) activities in a concentration- and time-dependent manner; however, it had little effect on spermidine/spermine N1-acetyl transferase (SSAT) activity. The change in biosynthetic enzyme activities were reflected in polyamine pools, as decreased putrescine and spermidine levels. There were no changes in spermine level. As expected, treatment of the cells with 4 nM estradiol induced ODC and AdoMetDC activities, and slightly decreased SSAT activity. Addition of endoxifen in combination with 4 nM estradiol led to even more dramatic decrease in ODC and AdoMetDC activities and reduction of putrescine and spermidine levels. These results support our hypothesis that endoxifen can act as an antiestrogen and suppress cell growth stimulatory effects of estradiol in ERα-positive breast cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4603.
Abstract 3860: New ovarian cancer susceptibility loci identified
Goode, Ellen L. , Song, Honglin , Lawrenson, Kate , Palmieri, Rachel T., Sellers, Thomas A. , Gayther, Simon A. , Chenevix‐Trench, Georgia , Ramus, Susan J. , Bolton, Kelly L. , Vierkant, Robert A. , Berchuck, Andrew , Tsai, Ya-Yu , Pharoah, Paul D.P. , Lawrenson, Kate

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 3860-3860

10.1158/1538-7445.am10-3860 Get It

Abstract Genome-wide association analyses have identified an ovarian cancer susceptibility locus near BNC2 at 9p22.2 (OR 0.82, p 5.1 × 10−19, Nat Genet 41:996-1000, 2009), based on 1,772 and 2,354 Stage I cases and controls, 4,803 and 5,237 Stage 2 cases and controls, and extensive Stage 3 analysis in independent samples. Here, we report on Stage 3 analysis of nine additional regions with Stage 2 results at p < 10−4. Stage 1 samples were genotyped using the Illumina 610Quad and imputed at up to 2 million SNPs; Stage 2 samples were genotyped on an Illumina iSelect of 22,790 SNPs. Stage 3 samples from 4,335 cases (including 2,197 serous subtype) and 5,951 controls (14 studies) were genotyped using Illumina or Sequenom at up to 32 SNPs on chromosomes 1, 2, 3, 7, 8, 11, and 17. No evidence of heterogeneity by study site was observed. Logistic regression revealed four regions with ordinal p ≤ 10−7 in all cases or serous subtype only. The most significant finding for all cases was for rs2072590 at 2q31.1 (all cases OR 1.15, p=8.1 × 10−13; serous only OR 1.19 p=9.0 × 10−13) which is located 3.8 kb 3-prime of HOXD3, a homeobox gene which also had an intronic SNP (rs2301301) with p=3.1 × 10−5 (all cases). Second, we observed a locus at 8q24.21 highlighted by rs10088218 (all cases OR 0.84, p=1.3 × 10−9; serous only OR 0.75 p=2.2 × 10−14). This locus resides on the opposite side of MYC and 1.3 Mb from the 8q24 regions harboring loci for other cancers, and is independent of the other cancer-associated variants (r2 < 0.02). Third, at 3q25.31, promising results were observed at rs2665390, a SNP intronic to TIPARP (TiPARP, TCDD-inducible poly(ADP-ribose) polymerase; all cases OR 1.19, p=8.7 × 10−7; serous only OR 1.26, p=3.2 × 10−8). Finally, at 17q21.32, rs9303542 was associated with risk particularly among serous cases (all cases OR 1.13, p=1.5 × 10−6; serous only OR 1.16 p=4.3 × 10−7); this SNP is intronic to SKAP1 (src kinase associated phosphoprotein 1). We evaluated the functional role of genes at these loci in ovarian cancer and normal ovarian epithelial cells and in an in vitro model of neoplastic initiation and progression from normal ovarian epithelial cells after CYMC and KRAS activation. Both BNC2 and TiPARP were down regulated in cancer versus normal cells (p=5 × 10−9 and p=3.4 × 10−5, respectively) suggesting that loss of function is required for cancer development. Over-expressing CMYC (at 8q24) induced neoplastic transformation of normal ovarian cells. Both BNC2 and TiPARP were down-regulated following CMYC over-expression and showed significant loss of function with further transformation after mutant KRAS activation (p=7.8 × 10−7 and p=6.3 × 10−4, respectively). These results emphasize the importance of genome-wide association studies and consortia for the identification of moderate-risk alleles in rare cancers. Importantly, our findings unravel the genetic components of this disease and suggest functionally-significant novel targets. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3860.
Abstract 2854: Genetic variation in stromal genes decorin and lumican and susceptibility to serous ovarian cancer
Amankwah, Ernest K. , Wang, Qinggang , Beesley, Jonathan, Johnatty, Sharon E. , Phelan, Catherine M., Cunningham, Julie M. , Vachon, Celine M. , Iversen, Edwin S., Schildkraut, Joellen M. , Goode, Ellen L. , Sellers, Thomas A. , Kelemen, Linda E. , Tsai, Ya-Yu , Fridley, Brooke L. , Webb, Penelope M. , Chenevix‐Trench, Georgia , Vachon, Celine M. , Vierkant, Robert A. , Berchuck, Andrew

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 2854-2854

10.1158/1538-7445.am10-2854 Get It

Abstract Introduction: Alterations in components of the stromal tissue that underlie the epithelium can initiate, promote or inhibit epithelial tumorigenesis. Decorin (DCN) and lumican (LUM) are stromal genes with reduced expression in serous ovarian cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in these genes may influence susceptibility to serous ovarian cancer. Methods: To test this hypothesis, we compared genotype frequencies of 11 tagSNPs in DCN and LUM between 397 Caucasian cases with primary serous ovarian cancer and 920 Caucasian controls in two studies conducted at Mayo Clinic and Duke University (discovery set). Associations were evaluated further in a third Caucasian population of 436 cases and 1,098 controls in Australia (replication set). TagSNPs were selected from unrelated Caucasian samples within HapMap based on the following criteria: (i) minor allele frequency ≥ 0.05, (ii) pairwise linkage disequilibrium (LD) of r2 ≥ 0.8, and (iii) location within, and 5kb upstream and downstream of, each gene region. Genotyping was performed using the Illumina GoldenGate™ assay and associations between SNPs and serous cancer were evaluated using unconditional logistic regression to estimate per allele odds ratios (OR) and 95% confidence intervals (95%CI). Untyped genotypes for DCN rs13312816 in the discovery set, and for DCN rs3138165 and LUM rs17018765 in the replication set, were imputed using the MACH software. Results: In the discovery set, we observed inverse associations between DCN rs3138165 (OR=0.7; 95%CI=0.5-1.0), DCN rs13312816 (OR=0.7; 95%CI=0.5-1.0), DCN rs516115 (OR=0.8; 95%CI=0.7-1.0) and LUM rs17018765 (OR=0.7; 95%CI=0.5-1.0) and risk of serous ovarian cancers (all Ptrend=0.06). Associations were confirmed in the replication set for DCN rs3138165 (OR=0.6; 95%CI=0.4-0.9; Ptrend=0.009), DCN rs13312816 (OR=0.7; 95%CI=0.5-0.9; Ptrend=0.01) and LUM rs17018765 (OR=0.6; 95%CI=0.4-0.9; Ptrend=0.008), but not for DCN rs516115 (Ptrend=0.20). To increase statistical power, data from the discovery and replication sets were combined (833 cases and 2,013 controls) following confirmation of no statistical heterogeneity in the ORs between study sites. In the combined sample, associations were strengthened for DCN rs3138165 (OR=0.7; 95%CI=0.5-0.9; Ptrend=0.002), DCN rs13312816 (OR=0.7; 95%CI=0.5-0.9; Ptrend=0.002), DCN rs516115 (OR=0.9; 95%CI=0.8-1.0; Ptrend=0.03) and LUM rs17018765 (OR=0.6; 95%CI=0.5-0.8; Ptrend=0.001). All four SNPs were in the same LD block on chromosome 12, suggesting that serous ovarian cancer susceptibility may be driven by a single, correlated variant in the region. Conclusion: The findings of this study suggest that genetic variation in DCN and LUM may influence susceptibility to serous ovarian cancer and contribute to the mounting evidence that supports the role of the stroma in epithelial ovarian cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2854.